1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends

OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018

  • June 2014
  • 177 pages
  • GlobalData
Report ID: 2216560

Summary

Table of Contents

OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018

Summary

Despite its considerable patient population, the acne market has been overlooked and remained stagnant for the last decade. There has been a lack of research efforts due to the perception of a poor return on investment for topical treatments, the mainstay of acne therapy. There is an array of treatment options for acne, though with the exception of isotretinoin, most only provide symptomatic relief as opposed to a curative or disease-modifying solution. However, isotretinoin is unable to serve a significant proportion of the acne market owed to its teratogenic nature, making its prescription for women of child-bearing age problematic.

In the past decade, there has been a shift in the acne market, with greater appreciation of its patient pool and potential for a lucrative payoff. Furthermore, there has been greater stress put on the social and psychological implications of the disease, which impact patients’ quality of life. As a result, R&D investments have been initiated by key pharmaceutical players.
Key strategies underway in the acne market include -
- Drive for combination therapies, for example, Galderma’s Epiduo (adapalene and benzoyl peroxide), which continues to experience rapid uptake.
- Expansion of the market into the pediatric population and for late-onset acne in women.
- A push towards disease-modifying therapies; for example, launch of AndroScience’s ASC-J9 androgen receptor degradation enhancer is anticipated to be a game-changer and is expected to rival isotretinoin, the current market leader for severe acne.

Highlights

Key Questions Answered

- How will the US and 5EU acne markets evolve over the forecast period from 2012 to 2018 in terms of sales and patient numbers?
- How will the launch of late-stage pipeline therapies such as ASC-J9 and Visonac shape the future treatment landscape?
- How do the clinical and commercial attributes of late-stage pipeline therapies compare to one another and against existing treatment options?
- Why has there been a void of R&D interest from Big Pharma in this highly populated dermatology indication?
- What are the remaining unmet needs and opportunities for drug developers within the acne space?

Key Findings

- The main drivers of growth in the acne market during the 2012-2018 forecast period include the launch of AndroScience’s ASC-J9, a therapeutic that is highly anticipated in the previously stagnant acne market and will make hormonal therapies available to males with acne, the continued success and uptake of Galderma’s Epiduo, and the launch of Photocure’s Visonac; potentially the first photodynamic therapy for use in acne.
- The lack of dedicated R&D programs in acne has been attributed to pharmaceutical companies viewing topicals, the mainstay of acne therapy, as being inexpensive, with a poor return on investment. Instead, R&D strategies have centered on reformulations of existing products and/or fixed-dose combination therapies, acquisitions of key dermatology products by Big Pharma, and label expansions into the previously untapped pediatric market. Targeting the pediatric market is a strategy that GlobalData expects will be used by other dermatology companies during the coming decade.
- A continued unmet need for acne is the need for new and innovative products to treat the underlying condition. Ideally, these products should be molecules that can specifically target critical pathways in the acne pathophysiology. Given the acne market’s substantial patient pool (estimated to be 103.9 million patients in the US and 5EU) and increasing understanding of the disease’s pathophysiology, GlobalData expects continued interest in the acne market from biotechs and pharmaceutical companies over the coming decade.

Scope

- Overview of acne, including epidemiology, etiology, pathophysiology, symptoms, and current treatment options.
- Annualized acne prescription therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2018.
- Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design, and benchmarking analysis for the acne prescription therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs. Accompanied by an interactive clinical and commercial benchmarking analysis tool.
- Analysis of the current and future market competition in the US and 5EU acne prescription therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Additionally a list of acquisition targets included in the early-stage pipeline products list.
- Develop business strategies by understanding the trends shaping and driving the US and 5EU acne prescription therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the US and 5EU acne prescription therapeutics markets in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track therapy sales in the US and 5EU acne prescription therapeutics markets from 2012-2018.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cutaneous T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025

  • $ 6950
  • Industry report
  • July 2017
  • by Delve Insight

DelveInsight’s “Actinic Keratosis– Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025”report provides the comprehensive insights on the competitive landscape and market ...

Radiodermatitis Market Analysis By Product (Topical, Corticosteroids, Hydrophilic Creams, Antibiotics, Dressings, Hydrogel & Hydrocolloid, No Sting Barrier Film, Silicone Coated), By Distribution Channel, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global radiodermatitis market is expected to reach USD 442.1 million by 2025, according to a new report by Grand View Research, Inc. The global radiodermatitis market is expected to grow at an unprecedented ...

Actinic Keratosis-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • May 2017
  • by Delve Insight

DelveInsight’s “Actinic Keratosis - Market Insights, Epidemiology and Market Forecast-2023-7MM” report provides an overview of the disease and global market size of the Actinic Keratosis for the ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.